9 Meters Biopharma Inc
OTC:NMTRQ
9 Meters Biopharma Inc
OTC:NMTRQ
Price:
0.0005
USD
Market Closed
Market Cap:
$1.4k
Income Statement
Earnings Waterfall
9 Meters Biopharma Inc
9 Meters Biopharma Inc
Income Statement
9 Meters Biopharma Inc
9 Meters Biopharma Inc
Currency: USD
| Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||||||||||||||
| Interest Expense |
2
|
1
|
1
|
1
|
1
|
1
|
2
|
1
|
1
|
0
|
0
|
0
|
0
|
4
|
5
|
6
|
6
|
3
|
2
|
2
|
2
|
2
|
3
|
4
|
4
|
4
|
3
|
0
|
0
|
0
|
0
|
1
|
3
|
3
|
|
| Revenue |
11
N/A
|
11
+1%
|
11
-6%
|
9
-18%
|
8
-6%
|
7
-10%
|
8
+5%
|
4
-43%
|
4
-8%
|
4
+10%
|
3
-33%
|
2
-21%
|
2
-20%
|
1
-50%
|
1
-20%
|
1
-19%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Gross Profit | |||||||||||||||||||||||||||||||||||
| Cost of Revenue |
(11)
|
(11)
|
(11)
|
(9)
|
(8)
|
(7)
|
(7)
|
(4)
|
(3)
|
(4)
|
(3)
|
(2)
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Gross Profit |
0
N/A
|
0
-22%
|
(0)
N/A
|
(1)
-139%
|
0
N/A
|
0
-30%
|
1
+113%
|
0
-69%
|
1
+270%
|
1
-14%
|
0
-73%
|
0
-94%
|
(0)
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||||||||||||||||||||
| Operating Expenses |
(7)
|
(8)
|
(8)
|
(8)
|
(7)
|
(6)
|
(7)
|
(7)
|
(7)
|
(7)
|
(8)
|
(7)
|
(7)
|
(17)
|
(19)
|
(18)
|
(18)
|
(10)
|
(13)
|
(19)
|
(26)
|
(26)
|
(33)
|
(32)
|
(29)
|
(61)
|
(25)
|
(27)
|
(32)
|
(43)
|
(46)
|
(41)
|
(42)
|
(43)
|
|
| Selling, General & Administrative |
(6)
|
(7)
|
(7)
|
(7)
|
(7)
|
(6)
|
(6)
|
(7)
|
(6)
|
(7)
|
(7)
|
(6)
|
(6)
|
(9)
|
(10)
|
(10)
|
(10)
|
(7)
|
(8)
|
(9)
|
(10)
|
(9)
|
(11)
|
(11)
|
(10)
|
(11)
|
(7)
|
(8)
|
(9)
|
(10)
|
(11)
|
(11)
|
(11)
|
(11)
|
|
| Research & Development |
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(6)
|
(8)
|
(6)
|
(8)
|
(2)
|
(4)
|
(10)
|
(14)
|
(15)
|
(12)
|
(13)
|
(11)
|
(12)
|
(17)
|
(18)
|
(22)
|
(27)
|
(29)
|
(29)
|
(31)
|
(32)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(9)
|
(9)
|
(8)
|
(39)
|
(0)
|
(0)
|
(0)
|
(6)
|
(6)
|
(1)
|
(1)
|
(0)
|
|
| Operating Income |
(7)
N/A
|
(8)
-16%
|
(8)
-7%
|
(9)
-3%
|
(6)
+25%
|
(6)
+4%
|
(6)
+3%
|
(7)
-16%
|
(6)
+15%
|
(7)
-15%
|
(8)
-11%
|
(7)
+12%
|
(7)
+0%
|
(16)
-136%
|
(19)
-19%
|
(17)
+9%
|
(18)
-7%
|
(10)
+45%
|
(13)
-27%
|
(19)
-53%
|
(26)
-31%
|
(26)
-3%
|
(33)
-25%
|
(32)
+1%
|
(29)
+12%
|
(61)
-114%
|
(25)
+60%
|
(27)
-9%
|
(32)
-18%
|
(43)
-35%
|
(46)
-7%
|
(41)
+11%
|
(42)
-3%
|
(43)
-3%
|
|
| Pre-Tax Income | |||||||||||||||||||||||||||||||||||
| Interest Income Expense |
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(2)
|
(2)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(4)
|
(5)
|
(6)
|
(6)
|
(1)
|
1
|
(1)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(0)
|
(0)
|
0
|
0
|
(1)
|
(2)
|
(2)
|
|
| Non-Reccuring Items |
0
|
(4)
|
(4)
|
(4)
|
(1)
|
0
|
0
|
1
|
1
|
1
|
1
|
0
|
(1)
|
(1)
|
0
|
0
|
0
|
(1)
|
(1)
|
(1)
|
(1)
|
0
|
(32)
|
(32)
|
(32)
|
0
|
0
|
(5)
|
(5)
|
0
|
0
|
0
|
(0)
|
(0)
|
|
| Total Other Income |
(3)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(11)
N/A
|
(14)
-22%
|
(14)
-3%
|
(14)
-2%
|
(9)
+38%
|
(8)
+14%
|
(8)
-1%
|
(8)
-5%
|
(6)
+22%
|
(7)
-6%
|
(7)
-6%
|
(7)
+5%
|
(8)
-19%
|
(21)
-160%
|
(23)
-12%
|
(23)
+3%
|
(24)
-7%
|
(12)
+48%
|
(13)
-2%
|
(21)
-66%
|
(27)
-28%
|
(26)
+3%
|
(66)
-153%
|
(65)
+1%
|
(62)
+6%
|
(63)
-3%
|
(27)
+57%
|
(32)
-19%
|
(37)
-14%
|
(43)
-16%
|
(46)
-7%
|
(41)
+9%
|
(44)
-6%
|
(46)
-6%
|
|
| Net Income | |||||||||||||||||||||||||||||||||||
| Tax Provision |
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(11)
|
(14)
|
(14)
|
(14)
|
(9)
|
(8)
|
(8)
|
(8)
|
(6)
|
(7)
|
(7)
|
(7)
|
(8)
|
(21)
|
(23)
|
(23)
|
(24)
|
(12)
|
(13)
|
(21)
|
(27)
|
(26)
|
(66)
|
(65)
|
(62)
|
(63)
|
(27)
|
(32)
|
(37)
|
(43)
|
(46)
|
(41)
|
(44)
|
(46)
|
|
| Net Income (Common) |
(11)
N/A
|
(14)
-22%
|
(14)
-3%
|
(14)
-2%
|
(9)
+38%
|
(8)
+14%
|
(8)
-1%
|
(8)
-5%
|
(6)
+22%
|
(7)
-6%
|
(7)
-6%
|
(7)
+5%
|
(9)
-33%
|
(22)
-144%
|
(24)
-12%
|
(23)
+3%
|
(24)
-3%
|
(12)
+48%
|
(13)
-2%
|
(21)
-66%
|
(27)
-28%
|
(26)
+3%
|
(66)
-153%
|
(65)
+1%
|
(62)
+6%
|
(63)
-3%
|
(27)
+57%
|
(32)
-19%
|
(37)
-14%
|
(43)
-16%
|
(46)
-7%
|
(41)
+9%
|
(44)
-6%
|
(46)
-6%
|
|
| EPS (Diluted) |
-276.5
N/A
|
-338
-22%
|
-349.5
-3%
|
-355.25
-2%
|
-218.5
+38%
|
-187.75
+14%
|
-189.75
-1%
|
-265
-40%
|
-207
+22%
|
-164.25
+21%
|
-174.25
-6%
|
-133
+24%
|
-176.4
-33%
|
-20.32
+88%
|
-18.84
+7%
|
-17.85
+5%
|
-19.48
-9%
|
-9.15
+53%
|
-7.48
+18%
|
-11.82
-58%
|
-16.19
-37%
|
-12.72
+21%
|
-16.87
-33%
|
-9.24
+45%
|
-11.64
-26%
|
-5.99
+49%
|
-2.16
+64%
|
-2.53
-17%
|
-3.03
-20%
|
-3.3
-9%
|
-3.51
-6%
|
-3.2
+9%
|
-3.38
-6%
|
-3.4
-1%
|
|
Switch to:
Switch to:
See Also
Discover More
